Skyworks Analysts Call Out Apple Content Gain And Broad Market Strength Post Mixed 1Q
Needham analyst Rajvindra Gill maintained Skyworks Solutions Inc (NASDAQ: SWKS) with a Buy and
3 Chegg Analysts Are Disappointed With Guidance: Are ChatGBT, AI Apps A Threat?
Shares of education tech firm Chegg Inc (NYSE: CHGG) plummeted in early trading on Tuesday, after the company reported quarterly results and guidance.
3 Take-Two Interactive Software Analysts Express Concern Around FQ3 Print, Guidance
Shares of Take-Two Interactive Software, Inc (NASDAQ: TTWO) climbed in early trading on Tuesday, despite the company reporting disappointing fiscal third-quarter results and lowering guidance.
Credit Suisse Double Upgrades This Defense Stock: What You Need To Know
Credit Suisse are double upgrading an aerospace and defense stock on the basis of a bullish growth outlook. Here's what investors need to know.
Former Hedge Fund Manager Lists 3 Reasons Berkshire Hathaway Has ‘Everything We Look For In A Stock’
Investment expert and former hedge fund manager Whitney Tilson, current president and CEO of Empire Financial Research, presented his bullish thesis on Warren Buffett holding company Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE:
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Needham has upgraded Personalis Inc (NASDAQ:PSNL) to Buy from Hold with a price target of $8. The analyst writes that Personalis’s cash…
PayPal Analyst Downgrades Stock Citing Branded Checkout Market Share Loss To Apple Pay
Raymond James analyst John Davis downgraded PayPal Holdings Inc (NASDAQ:PYPL) from Outperform to Market Perform. PayPal’s strong start in 2023 versus the…
China Fully Removes Macau Travel Restrictions, COVID-19 Testing Requirements: Here’s How To Play It
On Monday, China officially lifted all travel restrictions and limitations to Macau and scrapped COVID-19 texting requirements.
Macau casino operators are now hoping the end of pandemic restrictions will produce an extended period of pent-up demand among gamblers.
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…